Antibody-dependent killing of meningococci by human neutrophils in serum of late complement component-deficient patients.
BACKGROUND
Thirty-one Russian patients with late complement component deficiency (LCCD) who had experienced one to five meningococcal infections were immunized with meningococcal polysaccharide vaccine (A + C + W135 + Y) and were followed for 3-8 years. We investigated the potentially protective killing effect of human neutrophils (PMNL) on serogroup A and W135 meningococci.


METHODS
Meningococci were incubated in LCCD vaccine sera in the absence or presence of PMNL, and the number of live bacteria (CFU) was determined by plating onto chocolate agar.


RESULTS
When meningococci were incubated in the LCCD sera alone, exponential growth of meningococci occurred despite the presence of meningococcal antibodies. After the addition of PMNL, meningococci were inhibited in their growth or even eliminated. Group A or W135 meningococci were killed effectively by PMNL in 80% of the sera which were collected 1 month to 1 year after vaccination compared to only 40% in the prevaccination LCCD sera (p < 0.05). Three years after vaccination 67% of the LCCD sera were still capable of promoting killing (and even 90% after revaccination). The rate of killing correlated with the concentration of serogroup-specific immunoglobulins. In 83% of the 72 LCCD sera with more than 5 microg/ml anti-group A immunoglobulins the killing of group A meningococci was promoted. By contrast, only 21% of 19 samples with lower specific antibody levels showed a PMNL-mediated meningococcal killing (p < 0.05). The same effect was observed for group W135 meningococci.


CONCLUSIONS
PMNL kill meningococci during incubation in LCCD serum; this effect increases after vaccination and depends on both specific antibody and complement. Protection by vaccination may therefore be caused by an increased killing capacity of PMNL.
Platonov
Alexander E
AE
Central Institute of Epidemiology, Moscow, Russia. platonov@pcr.ru
Vershinina
Irina V
IV
Käyhty
Helena
H
Fijen
Cees A P
CA
Würzner
Reinhard
R
Kuijper
Edward J
EJ
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000276:immunology*; D003165:Complement System Proteins / Q000172:deficiency* / Q000276:immunology; D003601:Cytotoxicity Tests, Immunologic / Q000592:standards; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000097:blood / Q000276:immunology*; D008297:Male; D022401:Meningococcal Vaccines / Q000494:pharmacology*; D009345:Neisseria meningitidis / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology*
D022401:Meningococcal Vaccines; D003165:Complement System Proteins